Date recorded: August 20 2015

Duration: 41 minutes 59 seconds

This webinar introduces the Nanoparticle Tracking Analysis (NTA) technique and discusses how it can provide a range of useful characterization information for protein corona and self-assembled albumin-drug nanoparticles. Reviews of the latest literature for both protein corona and self assembled albumin-drug nanoparticles are presented. Finally, examples of NTA being used to characterize the size and counts of the protein corona and albumin-drug nanoparticles are shown.

Table of contents
1. Welcome
01:30
2. NTA Provides:
00:38
3. What I will cover today
00:56
4. Optical Arrangement for NanoSight Instruments
01:11
5. Particles are visualized, not imaged
00:00
6. Sizing: Stokes-Einstein
01:20
7. Concentration: Particles are Counted by Number
00:00
8. The biological significance of the protein corona
01:03
9. Nanoparticles are Exposed To Serum Proteins Upon Exposure to the Blood
00:44
10. The protein corona determines biological fate
01:04
11. Using a protein corona predictive model to predict biological fates.
01:15
12. Their Results and Conclusions
01:10
13. Examples: NTA data for Gold Nanorods dispersed in protein solutions.
00:49
14. Human Serum Albumin Coated Gold Nanorods
01:11
15. Citrate coated Gold Nanorods dispersed in fetal bovine serum
01:11
16. PEG coated Gold Nanorods dispersed in FBS
01:28
17. Example 2: Investigating analytical tools to measure protein conjugated nanoparticles: DLS and NTA.
01:59
18. Example 3: On-line protein corona characterization using SEC, MALS, NTA, ICP-MS
00:54
19. Protein corona conclusions
00:36
20. Human Serum Albumin as an Excipient Background
01:09
21. HSA properties cont.
00:49
22. Abraxane (nab-Paclitaxel), Albumin-bound paclitaxel.
01:51
23. Recent and exciting advances in albumin drug formulations.
01:11
24. Example 1
01:15
25. Example 2
00:50
26. Example 3
00:45
27. Example 4
00:34
28. Example 5
01:00
29. 2nd generation albumin drug formulations
00:21
30. Example 6
01:04
31. Example 7
00:55
32. Example 8
01:04
33. NTA Size and Particle Counts
01:06
34. A rapidly advancing field…
01:00
35. Conclusions
01:20
36. Thank you for your attentionAny questions?
05:43
37. Contact Information
01:03